BioCryst Pharma (BCRX) Misses Q4 EPS by 23c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.31 +1.86%
EPS Growth %: -13.3%
Financial Fact:
Total expenses: 17M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: -13.3%
Financial Fact:
Total expenses: 17M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.40), $0.23 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $79.5 million versus the consensus estimate of $75.57 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
- William Blair Upgrades Backblaze Inc (BLZE) to Market Perform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
